Eight Roads
Eight Roads is a global venture capital firm that operates as the proprietary investment arm of Fidelity International Limited. Founded in 1969, the firm has a strong presence in multiple regions, including Europe, Israel, China, India, Japan, and the United States. Eight Roads focuses on investing in early to growth-stage technology companies, particularly in sectors such as healthcare IT, financial services, software as a service (SaaS), and consumer technology. The firm typically invests between $1.29 million and $30 million, often taking minority stakes and seeking board representation in its portfolio companies. With offices in London, Hong Kong, and various cities across Asia, Eight Roads aims to support innovative companies poised for market success, leveraging its extensive network and industry expertise.
Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time.
Doceree Inc operates a programmatic advertising platform specifically designed for physician engagement. Founded in 2019 and headquartered in Parsippany, New Jersey, with an additional office in New Delhi, India, the company provides a fully integrated ad exchange that facilitates data-driven marketing targeted exclusively at physicians. By offering access to physician-only platforms, Doceree enables media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals to effectively purchase advertising space and reach their desired audiences.
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.
Transave
Venture Round in 2006
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
QUMAS delivers a closed-loop compliance model that standardizes and integrates the common elements of compliance tasks across the organization. Enterprises are able to effectively converge all of their compliance programs onto a single platform, radically reducing the cost of compliance and creating competitive advantage. With its proven track record in two of the of the most stringently regulated industries - financial services and life sciences - QUMAS has proven that it is best positioned to provide centralized compliance for any company, regardless of industry. Its solutions ensure corporate compliance with the full spectrum of global regulations.